GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 3,749 Shares

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) CFO Kevin Feeley sold 3,749 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79. Following the completion of the sale, the chief financial officer now owns 8,492 shares in the company, valued at $821,261.32. The trade was a 30.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

  • On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total value of $36,200.10.
  • On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total value of $87,331.84.
  • On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
  • On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92.
  • On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Price Performance

Shares of WGS traded down $4.01 during trading hours on Monday, hitting $94.46. 668,407 shares of the company were exchanged, compared to its average volume of 612,654. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. The firm has a fifty day simple moving average of $84.69 and a 200-day simple moving average of $70.37. GeneDx Holdings Corp. has a one year low of $7.72 and a one year high of $115.60.

GeneDx (NASDAQ:WGSGet Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on WGS. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

View Our Latest Analysis on WGS

Institutional Investors Weigh In On GeneDx

A number of large investors have recently made changes to their positions in WGS. MCF Advisors LLC boosted its stake in GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after purchasing an additional 182 shares during the period. Sterling Capital Management LLC boosted its position in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC purchased a new position in shares of GeneDx during the fourth quarter valued at $28,000. Lazard Asset Management LLC purchased a new position in shares of GeneDx during the fourth quarter valued at $35,000. Finally, Comerica Bank acquired a new position in GeneDx during the fourth quarter valued at $50,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Articles

Insider Buying and Selling by Quarter for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.